Symbols

PULM

Pulmatrix·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Ample Liquidity

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PULM

Pulmatrix, Inc.

A clinical-stage biopharmaceutical company that developing innovative inhaled therapies to treat and prevent the spread of infectious and progressive respiratory diseases

Industry

Pharmaceutical

Established Date

Listing Date

03/21/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pulmatrix.com

Security Type

Common stock

Office address

945 Concord Street, Suite 1217, Framingham, MA 01701

Business

Introduction

Pulmatrix, Inc., was incorporated as a Delaware corporation in 2013. The Company is a biopharmaceutical company focused on developing inhaled therapeutic products for central nervous system diseases and respiratory diseases using its patented iSPERSE dry powder delivery technology.

Company Financials

EPS

PULM has released its 2025 Q3 earnings. EPS was reported at -0.24, versus the expected 0, missing expectations. The chart below visualizes how PULM has performed over recent quarters, highlighting trends in earnings surprises.